MaaT Pharma

📄 [Press release] – MaaT Pharma is proud to announce that the final patient has been treated in the Phase 3 ARES clinical trial evaluating MaaT013 in treating acute Graft-versus-Host Disease (#aGvHD). Key highlights: ▪ Topline results expected in January 2025 ▪ Positive DSMB review with a favorable benefit/risk ratio noted for its high efficacy and low toxicity ▪ Registration process to commence in Europe in 2025 Our CEO, Hervé Affagard, shared: “We are confident that MaaT013 could become the first-ever approved therapy using microbiome-driven immune modulation in oncology.” 👉https://lnkd.in/emTAdyqE Stay tuned for further updates as we advance towards our goal of improving outcomes for patients with aGvHD. #microbiome #clinicaltrials #oncology #GvHD #innovation #MaaT013 #immunemodulation

📢 [#INTERNSHIP] - Join the #Bioinformatics department of MaaT Pharma as a Bioinformatician Intern (M/F)! The position is available immediately for a period of 4 to 6 months.   🎯 Are you pursuing a five-year degree in Bioinformatics or Quality Assurance? Do you have knowledge of R or Python programming languages, already used the Linux environment? Do you have document management skills, are you team player and detail-oriented?   👉 If this sounds like you, we’d love to hear from you! Be part of our mission and apply by sending your resume and cover letter to [email protected].   🔬 Detailed job description: see link in first comment 👇 Cyrielle Gasc Marianne Borderes

📢 [#STAGE] – Rejoignez le département #Bioinformatique de MaaT Pharma, en tant que Stagiaire Bioinformaticien (H/F) ! Stage de 4 à 6 mois, à pourvoir dès que possible ! 🎯 Vous préparez un Bac+5, en formation Bio-informatique ou Assurance Qualité ? Vous avez connaissance des langages de programmation R ou Python, déjà utilisé l’environnement Linux ? Vous avez des aptitudes en gestion documentaire, travaillez avec rigueur, et avec un bon esprit d’équipe ?   👉 Votre profil nous intéresse ! Prenez part à l’aventure MaaT Pharma et postulez en envoyant votre CV et lettre de motivation à [email protected].   🔬 Description détaillée du poste : lien dans le premier commentaire 👇 Cyrielle Gasc Marianne Borderes

📰 [Media] – “It’s really about taking an approach which has not been taken to date to change the trajectory of patients.” -  Herve Affagard, MBA, Eng., CEO and co-founder of MaaT Pharma.    In case you missed it, check out this fascinating article in Bloomberg Businessweek on how the #microbiome can be harnessed for #cancer care, and our role in pioneering this frontier in medicine. Read more: https://lnkd.in/gBbtJjG4 

🎥 Replay available!   Catch our virtual KOL event featuring Prof. Mohamad Mohty, MD, PhD (Saint-Antoine Hospital - AP-HP) and Dr. Monzr M. Al Malki, MD (City of Hope) as they discuss:  ✅ Unmet medical needs in acute Graft-versus-Host Disease (aGvHD),  ✅ Latest data on MaaT013 from the Early Access Program, presented at the 2024 ASH Annual Meeting,  ✅ The potential of microbiome immunomodulation in their clinical practice.    👉 https://lnkd.in/g4pbV6T2 #KOL #Webinar #Replay #ASH #aGvHD #Innovation #Hematology #Cancer #Microbiome #Oncology 

📢 Now LIVE - Join our virtual KOL discussion with Prof Mohamad Mohty and Dr. Al Malki as they discussed the high unmet medical needs in acute Graft-versus-Host Disease (#aGvHD) and the latest MaaT013 data presented at the 2024 #ASH Annual Meeting. Register here: https://lnkd.in/eUv7smZJ

📄 [Media] - The #microbiome is increasingly recognized as crucial for health and disease. What could it hold for the future of #cancer treatment? BioPharma Dive explores how MaaT Pharma is pioneering this area of research and the potential for the first approved therapy to harness microbiome-driven immune modulation in #oncology. Read more: https://lnkd.in/dgc2Y8SN

🎥 During #ASH24, our Chief Medical Officer, Gianfranco Pittari, MD PhD, was interviewed by BiotechTV about the critical unmet needs in treating acute Graft-versus-Host Disease (#aGvHD) and how MaaT013, our microbiome-based therapy, is making a difference. 🔗 Watch the full interview to learn more: link in the first comment! #MicrobiomeTherapies #ASH24 #Innovation #Hematology #Oncology

📄 [Communiqué de presse] – MaaT Pharma présente des données positives pour MaaT013 issues de son programme d’accès compassionnel lors du Congrès annuel 2024 de l’ASH 📅 Webinaire avec des experts le 17 décembre 2024 – Inscription ici 👉https://lnkd.in/eUv7smZJ Professeur Malard, professeur d’hématologie à l’hôpital Saint-Antoine (AP-HP) et à Sorbonne Université a détaillé les données actualisées portant sur 154 patients atteints de la maladie aiguë du greffon contre l’hôte (aGvH) traités avec MaaT013 : ▪ Taux de réponse durable à 28 jours : le taux de réponse globale gastro-intestinale était de 51 %, et le taux de réponse globale pour tous les organes était de 49 %. ▪  Survie à long terme : la survie globale était de 47 % à 12 mois et de 42 % à 24 mois. ▪ La médiane de survie globale chez les patients répondant à MaaT013 dans une population similaire à celle de l’étude ARES était de 444 jours, contre 42 jours chez les non-répondeurs. Historiquement, la médiane de survie globale avec la meilleure thérapie disponible après le Ruxolitinib est de 28 jours (Abedin et al., 2021). ▪  Résultats principaux de l’essai clinique pivotal de Phase 3 ARES attendus en janvier 2025. 👉Lien en premier commentaire pour accéder au communiqué de presse #Cancer #Oncologie #Microbiote #ASH2024 #GvHD #innovation #MaaT013 #immunemodulation

📄 [Press release] – MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at  ASH 2024 Annual Meeting 📅 KOL Webinar on December 17, 2024 – Register here👉: https://lnkd.in/eUv7smZJ Professor Malard, hematology professor at Saint-Antoine Hospital (AP-HP) and Sorbonne University, presented updated data on 154 patients with acute Graft-versus-Host Disease (aGvH) treated with MaaT013: ▪ Sustained High Response Rates at Day 28: Gastrointestinal Overall Response Rate (GI-ORR) was 51% and Overall Response Rate (ORR) for all organs was 49%. ▪ Long-Term Survival: Overall Survival (OS) was 47% at 12 months, and 42% at 24 months. ▪  Median OS among patients responding to MaaT013 within the ARES-like population was 444 days, compared to 42 days in non-responders. Historically, median OS to best available therapy following Ruxolitinib is 28 days (Abedin et al., 2021). ▪  Topline results for the ARES pivotal Phase 3 trial anticipated in January 2025. 👉Link in the first comment to read the press release #microbiome #oncology #GvHD #innovation #MaaT013 #immunemodulation #ASH2024 #cancer